Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe NHS rollout of Mounjaro for weight management is expanding in stages, with significant changes taking effect in 2025 and 2026. Cohort 2 of the phased programme activated on 23 June 2026, widening access to adults with a BMI of 35–39.9 alongside four or more qualifying conditions. That said, eligibility remains strict, waiting lists vary by area, and many people who could benefit will not qualify yet. These are prescription-only medicines; a prescriber assesses suitability, not a checklist you fill in yourself. This page sets out what the latest NHS Mounjaro news means in practice, who it affects, and what your options are if you don't meet the current criteria or simply can't wait.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
NICE recommended tirzepatide (Mounjaro) for NHS use in its appraisal TA1026, published in December 2024 and updated in September 2025. Rather than opening access to everyone who meets the licensed criteria at once, NHS England designed a phased rollout to manage supply and capacity. The first cohort went live in June 2025: adults with a BMI of 40 or above, alongside four or more of five specified conditions — high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes.
Cohort 2 then activated on 23 June 2026, bringing in adults with a BMI of 35–39.9 who also carry four or more of those same conditions. A third cohort is planned from around March 2027, covering adults with a BMI of 40 or above and three qualifying conditions rather than four. Lower BMI thresholds apply for South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds throughout each phase, at 2.5 kg/m² below the published figures.
On the prescribing side, a genuinely new development from April 2026 is that GPs can now prescribe tirzepatide directly under the updated QOF contract, rather than patients needing a referral to a specialist service. In practice, though, individual practices opted in voluntarily, so availability varies considerably depending on where you live. What a GP can and cannot prescribe on the NHS is worth reading if you're unsure what to ask your surgery.
Possibly, but the conditions are specific. You need to meet the BMI threshold for your current cohort, have the right number of qualifying comorbidities confirmed by your GP, and your practice needs to participate in the scheme. Meeting those criteria still doesn't guarantee access: every NHS patient on this treatment must take part in wrap-around lifestyle and dietary support, and ICB-level commissioning decisions affect what's actually available locally. The NHS page on weight-management injections sets out the eligibility requirements in full.
Most people asking about Mounjaro NHS news fall into one of three situations: they qualify and want to know the next step; they nearly qualify and want to understand the timeline; or they've looked at the criteria and realised they won't be eligible for some time. If you're in the third group, private prescribing is a legal and clinician-supervised route. A real prescriber still reviews your case — the medicine is prescription-only regardless of whether the NHS or a private pharmacy supplies it. Our broader guide to Mounjaro on the NHS covers both routes in more detail.
One practical note: if you're weighing up how quickly you might actually start treatment through the NHS versus privately, it's worth checking current waiting times at your local specialist service. Some areas report waits of many months even for patients who meet Cohort 1 criteria. If you want to understand what getting a private prescription actually involves, our guide to buying Mounjaro on the NHS and what to do if you don't qualify walks through both options clearly.
The clinical standard is the same: Mounjaro is a prescription-only medicine either way, licensed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. A prescriber reviews your health history, current medications and suitability before any treatment can be issued. What changes between routes is speed, wrap-around service structure, and cost.
Through the NHS you get treatment as part of a multidisciplinary programme, which is genuinely valuable, but you may wait a long time and must meet the phased BMI and comorbidity criteria. Privately, eligibility is based on the licensed criteria rather than the narrower NHS cohort thresholds, so the pool of people who qualify is wider. If cost is a factor, our Mounjaro price comparison sets out what a transparent private prescription typically includes and what to watch for when comparing providers.
At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber on the same day, a real clinician reads your answers before the afternoon post goes, not software triaging a queue. Order before 12pm on a weekday and, once clinically approved, your treatment is dispatched the same day and delivered free the next working day by DPD, tracked, in plain packaging. There are no subscriptions. Every repeat order goes back to a prescriber for clinical re-review. You can see who oversees our clinical programme on our clinical team page. If you want to understand what private treatment involves before committing to anything, our full Mounjaro guide is a good place to start.
Keep an eye on NHS England announcements and speak to your GP about where you currently sit relative to the phased criteria. Ask specifically whether your surgery has opted into the new QOF arrangement, many patients don't know it exists. If you have the relevant comorbidities and your BMI is close to a threshold, your GP can document those conditions formally, which matters when cohort eligibility is assessed.
It's also sensible to verify any online pharmacy you're considering, regardless of which route you take. The GPhC maintains a public register of every registered pharmacy premises in the UK; nume's registration can be verified directly. The MHRA has warned repeatedly about counterfeit weight-loss pens sold online and through social media, fake pens are a serious safety risk, not just a consumer nuisance. Any seller offering these medicines without a prescription, or at prices far below the market, is a red flag. Report anything suspicious via the Yellow Card scheme. For a fuller picture of your options right now, our guide to buying Mounjaro through a regulated UK pharmacy covers what to look for. When you're ready to check whether private treatment is appropriate for you, the best first step is a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.